Panasonic Develops Assist Robots
Panasonic released a video featuring its assist robots, which support the everyday lives of workers and the elderly. The company has applied the advanced control and sensor technologies that it has developed to create a robot equipped with motors that assist human body mechanics. These robots are safe to use and offer peace of mind. This video highlights the latest developments in Panasonic’s assist robots.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160317005452/en/
Back support offering Assist Suit: AWN-03 was developed to provide lower back support. When lifting and holding heavy objects, it reduces stress on the user's lower back by 15kg. (Photo: Business Wire)
[Video] Panasonic Assist Robots
Assist Robots for Industrial Use
Power assist suits for industrial use have been developed by Activelink Co., Ltd., one of Panasonic's in-house venture companies.
“Our mission is to help realize a Power Barrier-less Society by offering a helping hand during manual labor and at other worksites" said Hiromichi Fujimoto, President of Activelink Co., Ltd. “We are proposing robotics to help at these worksites, because there will always be a certain level of work that must be done by people, and these power assist suits can help reduce the physical strain during such work”.
AWN-03: Back support offering Assist Suit
The AWN-03 was especially developed to provide lower back support. It automatically senses the user's motion when lifting and holding heavy objects, and sends a signal to the motors to rotate the gears. It also raises the user's upper body while pushing on their thighs, and as a result reduces stress on the user's lower back by 15kg.
By mimicking human motion, the PLN-01 named “Ninja” assists the user's motion while walking and running, for instance hiking up steep mountain paths during afforestation. An upper body unit of the “Ninja” is currently being developed, which will help lift and carry heavy items.
The Power Loader is a powerful suit that can be used during disaster relief, construction, and public works. It has 4 sensors in the hands and feet that control 20 motors.
Assist Robots for Elderly Care
Panasonic has been in the nursing business for over 18 years in Japan running elderly care facilities and developing devices that contribute to elderly care. Elderly care may be mentally and physically straining for people who give and receive care, so Panasonic is providing solutions that improve the quality of life of both the elderly and caregivers.
“As Japan has becomes an aging-society, Panasonic is aspiring to make its contribution by supporting the elderly and their families lead a comfortable life full of smiling faces and laughter” explained Hitoshi Sasaki, Assistant Director of Sincere Kourien, an elderly care facility run by Panasonic AGE-FREE. “There are many instances that can be straining to both caregivers and care recipients. Just moving from the bed to a wheelchair can be a very energy consuming both parties."
Panasonic developed Resyone, a combination of electric nursing care bed and an electric full reclining wheelchair. Resyone's bed splits in half and one half transforms into a reclining wheelchair. Caregivers no longer have to lift residents from the bed to the wheelchair, so it reduces the strain on both the caregiver and residents and also helps maintains residents’ dignity.
Resyone became the world’s first product to receive the ISO13482 certification, the new global safety standard for personal care robots.
Self-Reliance Support Robot
The Self-Reliance Support Robot assists the elderly when moving from the bed to the restroom, chairs etc. and empowers them to perform everyday tasks, such as using the restroom and watching television. This robot senses the slightest of movement and can predict how the elderly is doing based on the information gathered by the sensors. The motors in this robot only provide the level of power necessary, that is lacking, allowing residents to use their own remaining muscle strength and thereby prevents unnecessary muscle atrophy and strain. The robot also reduces strain for the caregiver as well, because they will no longer have to use their own physical strength.
To help realize a better life, Panasonic will continue to develop robots that provide assistance in a wide range of fields that are safe to use and offers peace of mind.
Activelink Co., Ltd
Panasonic Introduces Its Advanced Care Solutions "For Nursing Care and
Lifestyles of the Future" - H.C.R. 2015
Panasonic Solutions for Seniors
Global Communications Department
Media Promotion Office
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi
Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00 | Pressemelding
The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005050/en/ Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements